Prokinecitine in Acute Myocardial Infarction (Prok-Idm)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by University Hospital, Strasbourg, France
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT02021487
First received: December 19, 2013
Last updated: NA
Last verified: December 2013
History: No changes posted
  Purpose

The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.


Condition
ST Elevatation Myocardial Infarction (STEMI)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • Infarct size by MRI necrotic myocardial mass [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    Infarct size by MRI necrotic myocardial mass


Estimated Enrollment: 200
Study Start Date: November 2013
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with acute St elevation myocardial infarction of less than 6 hours

Criteria

Inclusion Criteria:

  • Patients with acute St elevation myocardial infarction of less than 6 hours
  • Age>18 y/o

Exclusion Criteria:

  • Previous myocardial infarction
  • LBB, RBB
  • Renal Insuffiency MDRD<30 mL/min
  • Patient with Pace-Maker or ICD.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02021487

Contacts
Contact: Patrick OHLMANN, MD 03 69 55 09 53 ext 0033 patrick.ohlmann@chru-strasbourg.fr

Locations
France
University Hospital Recruiting
Strasbourg, France, 67000
Contact: Patrick OHLMANN, MD         
Principal Investigator: Patrick OHLMANN, MD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Patrick OHLMANN, MD University Hospital, Strasbourg, France
  More Information

No publications provided

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT02021487     History of Changes
Other Study ID Numbers: 5515
Study First Received: December 19, 2013
Last Updated: December 19, 2013
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 18, 2014